

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)
)
Peter HERMENTIN et al.) Group Art Unit: To Be Assigned
)
Application No.: To Be Assigned) Examiner: To Be Assigned
)
Filed: Concurrent Herewith)
)
For: METHOD FOR DETERMINING)
MULTIMERS OF PLASMA)
PROTEINS)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(b)

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), Applicants bring to the attention of the Examiner the documents listed on the attached PTO 1449. This Information Disclosure Statement is being filed within three months of the filing date of the above-referenced application.

Copies of the listed documents, including any copending patent applications, are attached. Applicants respectfully request that the Examiner consider the listed documents and indicate that they were considered by making appropriate notations on the attached form.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If the Examiner applies any of the

documents as prior art against any claim in the application and Applicants determine that the cited documents do not constitute "prior art" under United States law, applicant reserves the right to present to the office the relevant facts and law regarding the appropriate status of such documents.


Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

If there is any fee due in connection with the filing of this Statement, please charge the fee to our Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.

Dated: October 7, 2003

By: 
Carol Einaudi
Reg. No. 32,220

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

INFORMATION DISCLOSURE CITATION

| | | | |
|------------------|------------------------|------------|----------------|
| Atty. Docket No. | 06478.1495-00000 | Appln. No. | To Be Assigned |
| Applicant | Peter HERMENTIN et al. | | |
| Filing Date | Concurrent Herewith | Group: | To Be Assigned |

| U.S. PATENT DOCUMENTS | | | | | | | |
|-----------------------|--|-----------------|------------|------|-------|-----------|----------------------------|
| Examiner Initial* | | Document Number | Issue Date | Name | Class | Sub Class | Filing Date If Appropriate |
| | | | | | | | |

| FOREIGN PATENT DOCUMENTS | | | | | | | |
|--------------------------|--|-----------------|------------------|---------|-------|-----------|-----------------------|
| | | Document Number | Publication Date | Country | Class | Sub Class | Translation Yes or No |
| | | WO 01/12244 A1 | 22 Feb. 2001 | PCT | | | |
| | | | | | | | |

| OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) | |
|--|---|
| | CONNAGHAN, D. G. et al., "Specific Identification of Fibrin Polymers, Fibrinogen Degradation Products, and Crosslinked Fibrin Degradation Products in Plasma and Serum With a New Sensitive Technique," <i>Blood</i> , Vol. 65 (3): 589-597 (1985). |
| | PROIETTI, A. B. et al., "Specific Identification of Fibrin(ogen) Degradation Products in Plasma and Serum Using Blotting and Peroxidase Labeled Antiserum," <i>American Journal of Hematology</i> , Vol. 34:270-274 (1990). |
| | RAINES, G. et al., "Multimeric Analysis of Von Willebrand Factor By Molecular Sieving Electrophoresis in Sodium Dodecyl Sulphate Agarose Gel," <i>Thrombosis Research</i> , Vol. 60:201-212 (1990). |
| | METZNER, H. J. et al., "Characterization of Factor VIII/von Willebrand Factor Concentrates Using a Modified Method of von Willebrand Factor Multimer Analysis," <i>Haemophilia</i> , Vol. 4(3): 25-32 (1998). |
| | COON, M. R. et al., "A Technique for von Willebrand Multimer Analysis Applicable to the Clinical Laboratory," <i>Clin Appl Thrombosis/Hemostasis</i> , Vol. 1(1): 31-33 (1995). |
| | TATEWAKI, W. et al., "Plasma von Willebrand Factor Proteolysis in Patients with Chronic Myeloproliferative Disorders: No Possibility of Ex Vivo Degradation by Calcium-Dependent Proteases," <i>Thrombosis Research</i> , Vol. 56:191-199 (1989). |
| | RUGGERI, Z. M. et al., "The Complex Multimeric Composition of Factor VIII/ von Willebrand Factor," <i>Blood</i> , Vol. 57(6): 1140-1143 (1981). |
| | PERUTELLI, P., "Immunostaining of von Willebrand Factor Multimers On Agarose Gels and Nitrocellulose Filters," <i>Haematologica</i> , Vol. 87: 223-224 (2002). |

| | |
|---|---|
| Examiner | Date Considered |
| *Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | |
| Form PTO 1449 | Patent and Trademark Office - U.S. Department of Commerce |